Skip to main content
Signal8

T2 Biosystems, Inc. (TTOO)

T2 Biosystems, Inc. is an in vitro diagnostics company that develops and commercializes innovative diagnostic solutions for global markets. Its proprietary technology platform enables the rapid detection of pathogens, biomarkers, and other critical abnormalities directly from a wide array of unpurified patient specimens, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid, and urine. The company's commercial offerings include the T2Dx Instrument, a compact bench-top system designed to run various diagnostic assays. Its current suite of diagnostic tests features T2Candida, a direct-from-blood test that rapidly identifies bloodstream infections leading to sepsis and candidemia; T2Bacteria, another direct-from-blood assay for detecting bacterial pathogens commonly associated with sepsis; T2Resistance, which targets and identifies genes conferring carbapenem resistance; and the T2SARS-CoV-2 panel, developed to detect the SARS-CoV-2 virus. In addition to its existing products, T2 Biosystems is actively advancing several diagnostic candidates. These include T2Biothreat, aimed at identifying biothreat pathogens; a comprehensive sepsis panel designed to detect bloodstream infections caused by both bacterial and Candida species, along with antibiotic resistance markers; T2Cauris, which offers direct detection of the emerging superbug Candida auris in patient skin, blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel specifically engineered for the T2Dx Instrument to identify the bacteria responsible for Lyme disease. T2 Biosystems has also established strategic partnerships, such as its collaboration with Canon U.S. Life Sciences, Inc., to jointly develop a diagnostic test panel for Lyme disease. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Sector: Medical - Diagnostics & Research

Industry: Medical - Diagnostics & Research

T2 Biosystems, Inc. logo

T2 Biosystems, Inc.

OTC:TTOOHealthcare
$0.0004
CLOSED
Mkt Cap$11K
EV-
Float28.05M
O/S28.05M
VOL1K sh
$ Vol$2
RVOL0.07×
Inst Own0.0%
SI<0.1%
Net Cash/Sh-
Dilution
T2 Biosystems, Inc. logoOTC:TTOOClosed$0.0004
Financials Summary
Revenue$7.19M
Net Income-$50.08M
Total Assets$34.8M
Free Cash Flow-$48.33M
Debt & Equity
Debt 231%
Total Debt$49.5M
Total Equity-$28.04M
Shares Outstanding
Short Interest
Split History2 splits · 2 reverse
  1. 1:100Reverse split
    Oct 13, 2023100 shares → 1
  2. 1:50Reverse split
    Oct 13, 202250 shares → 1
Balance Sheet Details
Assets$34.8M
Liabilities$62.83M
Accounts Receivable$1.42M
Accounts Payable$1.53M
Inventory$4.82M
PP&E (Net)$9.05M
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Revenue$7.19M$22.3M$28.06M$18.13M$8.34M$10.5M$4.67M$4.08M$2.81M$119K$266K$19K
YoY Growth-67.8%-20.5%54.8%117.5%-20.6%125.0%14.4%45.0%2263.9%-55.3%1300.0%-
Cost of Revenue$15.36M$21.14M$20.7M$21.28M$16.76M$15.4M$12.03M$6.87M$1.74M$19.78M$14.94M$11.73M
Gross Profit-$8.17M$1.17M$7.36M-$3.15M-$8.43M-$4.9M-$7.36M-$2.79M$1.07M-$19.66M-$14.67M-$11.71M
Gross Margin-113.6%5.2%26.2%-17.4%-101.1%-46.7%-157.8%-68.4%38.1%-16523.5%-5515.0%-61621.1%
Research and Development$14.15M$25.93M$21.8M$16.92M$16.33M$14.49M$23.73M$24.01M$25.36M$19.78M$14.94M$11.73M
Selling, General, and Administrative$24.83M$30.74M$28.53M$21.29M$27.3M$25.7M$22.76M$24.08M$19.09M$11.02M$5.02M$2.94M
Other$2.51M$0$0$0$0$0$331K$172K$60K$12K-$515K$352K
Total Operating Expenses$41.49M$56.68M$50.33M$38.21M$43.63M$40.19M$46.49M$48.09M$44.46M$30.8M$19.96M$14.67M
Operating Income (EBIT)-$49.66M-$54.05M-$42.97M-$41.36M-$52.06M-$45.09M-$53.85M-$50.88M-$43.38M-$30.68M-$19.69M-$14.65M
Operating Margin-690.4%-242.3%-153.2%-228.1%-624.6%-429.4%-1154.1%-1247.0%-1542.2%-25782.4%-7403.0%-77121.1%
Interest Expense$5.34M$6.08M$7.6M$5.5M$7.35M$6.68M$8.91M$4.1M$1.97M$721K$403K$154K
Interest Income$0$0$112K$0$0$0$0$0$0$0$0$0
Other Income (Expense)-$413K-$6.81M-$6.27M-$5.44M-$6.95M-$6.06M-$8.58M-$3.93M-$1.91M-$709K-$918K$198K
Income Before Tax (EBT)-$50.08M-$62M-$49.24M-$46.8M-$59.01M-$51.15M-$62.43M-$54.8M-$45.29M-$31.39M-$20.61M-$14.46M
Income Tax Expense$0$0$0$0$0$0$0$0$0$42K-$112K$0
Net Income-$50.08M-$62M-$49.24M-$46.8M-$59.01M-$51.15M-$62.43M-$54.8M-$45.29M-$31.39M-$20.61M-$14.46M
Net Income Margin-696.2%-278.0%-175.5%-258.1%-707.9%-487.2%-1337.9%-1343.2%-1610.0%-26378.2%-7748.1%-76078.9%
Supplementary Data
EPS-19.19-1222.14-1549.82-1928.54-6934.20-126.12-194.29-210.66-220.91-361.85-1476.89-103.27
Diluted EPS-19.19-1222.14-1549.82-1928.54-6934.20-126.12-194.29-210.66-220.91-361.85-1476.89-103.27
Weighted Average OS2.61M51,00331,77224,2669,101405,588321,315260,157205,01786,74913,955139,969
EBITDA-$43.88M-$54.87M-$41.13M-$36.71M-$48.3M-$41.96M-$50.58M-$48.43M-$41.86M-$29.98M-$19.62M-$13.73M
EBITDA Margin-610.0%-246.0%-146.6%-202.5%-579.5%-399.6%-1084.0%-1186.9%-1488.0%-25191.6%-7377.1%-72263.2%
Balance Sheet
PeriodFY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Assets
Current Assets
Cash and Cash Equivalents$15.69M$10.33M$22.25M$16.79M$11.03M$50.8M$41.8M$73.49M$73.66M$73.85M$30.2M$9.71M
Short-Term Investments$0$0$10M$25.4M$0$0$0$0$0$0$0$0
Cash and Short-Term Investments$15.69M$10.33M$32.24M$42.19M$11.03M$50.8M$41.8M$73.49M$73.66M$73.85M$30.2M$9.71M
Accounts Receivable$1.42M$2.16M$5.13M$5.1M$2.83M$1.79M$467K$327K$369K$201K$0$0
Inventory$4.82M$4.35M$3.91M$3.64M$3.6M$2.68M$1.34M$803K$683K$115K$0$0
Other Current Assets$0$2.58M$0$0$0$1.34M$708K$820K$860K$80K$0$80K
Total Current Assets$25.19M$19.42M$44.39M$53.58M$18.89M$56.61M$44.32M$75.44M$75.57M$75.32M$30.39M$9.85M
Long-Term Assets
Property, Plant & Equipment Net$9.05M$13.27M$14.44M$14.8M$9.21M$7.32M$10.02M$13.59M$10.65M$2.76M$1.12M$1.2M
Goodwill$0$0$0$0$0$0$0$0$0$0$0$0
Intangible Assets$0$0$0$0$0$0$0$0$0$0$0$0
Long-Term Investments$651K$1.65M$1.55M$10M$0$0$260K$260K$260K$0$0$0
Deferred Tax Assets$0$0$0$0$0$0$0$0$0$313K$0$0
Other Long-Term Assets-$96K$43K$153K$687K$386K$386K$268K$281K$459K$427K$374K$387K
Total Long-Term Assets$9.61M$14.97M$16.14M$25.49M$9.59M$7.7M$10.54M$14.13M$11.37M$3.5M$1.49M$1.58M
Other Assets$0$0$0$0$0$0$0$0$0$0$0$0
Total Assets$34.8M$34.39M$60.54M$79.08M$28.49M$64.31M$54.86M$89.57M$86.95M$78.82M$31.89M$11.43M
Liabilities
Current Liabilities
Accounts Payable$1.53M$1.3M$2.83M$2.06M$3.75M$744K$648K$962K$1.23M$735K$943K$571K
Short-Term Debt$41.28M$0$0$0$42.9M$42.37M$40.7M$1.27M$4.47M$295K$1.76M$820K
Current Income Tax Payable$0$0$0$0$0$0$0$0$0$0$0$0
Current Unearned Revenue$224K$172K$518K$230K$285K$697K$1.74M$2.44M$2.15M$80K$0$0
Other Current Liabilities$8.8M$39K$0$0$8.46M$5.28M$5.91M$4.86M$3.49M$2.22M$25K$234K
Total Current Liabilities$56.15M$10.13M$11.69M$9.8M$60.57M$52.3M$51.78M$9.88M$12.28M$4.86M$4.05M$2.13M
Long-Term Liabilities
Long-Term Debt$0$49.65M$47.79M$45.23M$0$0$1.01M$39.5M$26.22M$20.66M$3.3M$5.06M
Long-Term Unearned Revenue$83K$52K$28K$424K$46K$133K$0$0$0-$207K$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0-$492K$0$0$0$313K$0$0
Other Long-Term Liabilities$0$5.94M$4.58M$4.36M$0$0$0$49K$436K$301K$114.08M$66.9M
Total Long-Term Liabilities$6.68M$63.85M$61.75M$60.55M$1.92M$625K$1.74M$40.34M$27.73M$20.96M$117.38M$71.96M
Other Liabilities$0$0$0$0$0$0$0$0$0$0$0$0
Total Liabilities$62.83M$74.36M$73.44M$70.35M$62.49M$52.92M$53.52M$50.23M$40.01M$25.82M$121.43M$74.09M
Stockholders' Equity
Preferred Stock$0$0$0$0$0$0$0$0$0$0$114.04M$66.83M
Common Stock$4K$8K$166K$147K$49K$44K$36K$30K$24K$20K$1K$1K
Retained Earnings-$584.3M-$534.53M-$472.22M-$422.98M-$376.18M-$317.17M-$266.12M-$203.69M-$148.88M-$103.59M-$89.54M-$62.66M
Comprehensive Income & Other$0$0-$4K$9K$0-$11.31M-$9.12M-$7.07M-$4.81M-$3.34M-$2.65M-$2.08M
Other Stockholders' Equity$556.26M$494.56M$459.15M$431.55M$342.12M$328.51M$267.42M$243M$195.8M$156.58M$0$0
Total Equity-$28.04M-$39.97M-$12.9M$8.73M-$34.01M$11.39M$1.34M$39.34M$46.94M$53M-$89.54M-$62.66M
Minority Interest$0$0$0$0$0$0$0$0$0$0$0$0
Total Liabilities and Equity$34.8M$34.39M$60.54M$79.08M$28.49M$64.31M$54.86M$89.57M$86.95M$78.82M$31.89M$11.43M
Supplementary Data
Total Debt$49.5M$59.22M$58.32M$56.92M$44.77M$43.13M$42.68M$41.87M$32.04M$20.95M$5.06M$5.88M
Net Debt$33.81M$48.89M$36.08M$40.13M$33.74M-$7.67M$882K-$31.62M-$41.63M-$52.89M-$25.14M-$3.83M
Cash Flow Statement
PeriodFY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Operating Activities
Net Income-$50.08M-$62M-$49.24M-$46.8M-$59.01M-$51.15M-$62.43M-$54.8M-$45.29M-$31.39M-$20.61M-$14.46M
Depreciation & Amortization$859K$1.05M$2.54M$3.16M$3.64M$2.45M$2.94M$2.28M$1.47M$691K$584K$571K
Deferred Income Tax$0$0-$1.02M-$258K$280K$613K$4.81M$112K$0$1K$536K-$51K
Stock-Based Compensation$4.35M$6.49M$7.09M$3.91M$5.46M$9.9M$4.79M$4.85M$4.17M$1.65M$578K$403K
Changes in Working Capital:
  Accounts Receivable$743K$2.97M-$35K-$2.27M-$1.04M-$1.32M-$140K$42K-$168K-$201K$0$0
  Inventory-$744K-$949K-$1.94M$441K-$914K-$1.09M-$110K-$120K-$568K-$115K$0$0
  Accounts Payable$231K-$1.57M$761K-$1.65M$2.96M$121K-$314K-$61K$177K-$208K$372K-$88K
  Other Working Capital-$4.27M-$959K-$957K-$3.05M$851K-$1.66M$140K$947K$2.52M$1.27M$448K$256K
Total Working Capital Change-$4.04M-$503K-$2.17M-$6.54M$1.86M-$3.94M-$424K$808K$1.96M$744K$820K$168K
Other Non-Cash Items$773K$4.34M$3.93M$3.31M$2.41M$2M$2.6M$314K$235K$117K$39K$61K
Net Cash from Operating-$48.14M-$50.63M-$38.87M-$43.22M-$45.36M-$40.14M-$47.72M-$46.44M-$37.47M-$28.18M-$18.05M-$13.3M
Investing Activities
Capital Expenditures-$192K-$339K-$460K-$804K-$761K-$593K-$2.48M-$5.49M-$7.97M-$2.08M-$513K-$283K
Acquisitions$0$0$0$4K$0$0$0$0$0$0$0$0
Purchases of Investments$0$0$0-$50.71M$0$0$0$0$0$0$0$0
Sales of Investments$0$10M$25.25M$15.25M$0$0$0$0$0$0$0$0
Other Investing Activities$0$0$0$0$0$0$0$0$80K$0$80K$0
Net Cash from Investing-$192K$9.66M$24.79M-$36.26M-$761K-$593K-$2.48M-$5.49M-$7.89M-$2.08M-$433K-$283K
Financing Activities
Debt Repaid----$882K$1.55M$1.19M-$11.4M-$9.69M-$15.68M$848K-$4.55M
Common Stock Issuance$52.73M$29.63M$19.97M$85.31M$6.65M$49.24M$18.64M$40.36M$35.48M$58.24M$55K$1K
Common Stock Repurchases$0-$330K$0$0$0$0$0$0$0$0$0$0
Dividends Paid$0$0$0$0$0$0$0$0$0$0$0$0
Other Financing Activities-$43K-$78K$567K$296K$582K$1.97M$1.06M$40.36M$0$0$39.82M$0
Net Cash from Financing$52.69M$29.05M$20.54M$85.61M$6.35M$49.66M$18.5M$51.76M$45.17M$73.92M$38.98M$4.55M
Forex Effect$0$0$0$0$0$0$0$0$0$0$0$0
Net Change in Cash$4.36M-$11.92M$6.45M$6.13M-$39.77M$8.93M-$31.69M-$174K-$187K$43.65M$20.49M-$9.04M
Supplementary Data
Operating Cash Flow-$48.14M-$50.63M-$38.87M-$43.22M-$45.36M-$40.14M-$47.72M-$46.44M-$37.47M-$28.18M-$18.05M-$13.3M
Capital Expenditure-$192K-$339K-$460K-$804K-$761K-$593K-$2.48M-$5.49M-$7.97M-$2.08M-$513K-$283K
Free Cash Flow-$48.33M-$50.97M-$39.33M-$44.02M-$46.12M-$40.73M-$50.19M-$51.93M-$45.44M-$30.27M-$18.57M-$13.59M
Cash at Beginning$11.88M$23.8M$17.34M$11.21M$50.98M$42.06M$73.49M$73.66M$73.85M$30.2M$9.71M$18.74M
Cash at End$16.24M$11.88M$23.8M$17.34M$11.21M$50.98M$41.8M$73.49M$73.66M$73.85M$30.2M$9.71M